Hexanedioic acid mono-(3,5-di-tert-butyl-4-hydroxy-phenyl) ester | 39160-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: Hexanedioic acid mono-(3,5-di-tert-butyl-4-hydroxy-phenyl) ester
• 英文别名: 6-(3,5-Ditert-butyl-4-hydroxyphenoxy)-6-oxohexanoic acid
• CAS: 39160-16-2
• 化学式: C₂₀H₃₀O₅
• 分子量: 350.455
• InChiKey: LDDXRGYXAHZTEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Aryl and heteroaryl compounds, compositions, methods of use
  申请人：Mjalli M.M. Adnan

  公开号：US20050171148A1

  公开（公告）日：2005-08-04

  This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX and/or XI.

  这项发明提供了芳基和杂环芳基化合物，以及它们的制备方法、包含这些化合物的药物组合物，以及它们在治疗人类或动物疾病中的应用。该发明的化合物可能用作因子IX和/或因子XI的拮抗剂或部分拮抗剂，因此可以用于抑制血液凝固的内在途径。这些化合物可能在多种应用中有用，包括利用因子IX和/或XI的内在凝血途径部分引起的疾病的管理、治疗和/或控制。
• Aryl and heteroaryl compounds, compositions, and methods of use
  申请人：Mjalli M.M. Adnan

  公开号：US20070254916A1

  公开（公告）日：2007-11-01

  This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX and/or XI.

  本发明提供了芳基和杂环芳基化合物，其制备方法，包含这些化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。该发明的化合物可能作为因子IX和/或因子XI的拮抗剂或部分拮抗剂而有用，因此可以用于抑制血液凝固的内在途径。这些化合物可以用于各种应用，包括利用因子IX和/或XI的内在凝血途径引起的疾病的管理、治疗和/或控制。
• Flame retardant and stabilizer combined for thermoplastics polymers
  申请人：Clariant GmbH

  公开号：US20040227130A1

  公开（公告）日：2004-11-18

  The invention relates to a novel flame retardant and stabilizer combined, for thermoplastics, which comprises, as component A, from 25 to 99.9% by weight of a phosphinic salt of the formula (I) and/or a diphosphinic salt of the formula (II) and/or polymers of these, 1 where R 1 , R 2 are identical or different and are C 1 -C 6 -alkyl, linear or branched, and/or aryl; R 3 is C 1 -C 10 -alkylene, linear or branched, C 6 -C 10 -arylene, -alkylarylene or -arylalkylene; M is Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na, K, and/or a protonated nitrogen base; m is 1 to 4; n is 1 to 4; x is 1 to 4, and comprises, as component B, from 10 to 75% by weight of a nitrogen-containing synergist or of a phosphorus/nitrogen flame retardant, and comprises, as component C, from 0.1 to 50% by weight of a basic or amphoteric oxide, hydroxide, carbonate, silicate, borate, stannate, mixed oxide/hydroxide, oxide/hydroxide/carbonate, hydroxide/silicate, or hydroxide/borate, or a mixture of these substances, and comprises, as component D, from 0 to 5% by weight of a mixture composed of a phosphonite or of a phosphonite/phosphite mixture, and comprises, as component E, from 0 to 5% by weight of an ester or a salt of montan wax acid, and comprises, as component F, from 0.1 to 5% by weight of an aromatic di- or tricarboxylic ester or aromatic di- or tricarboxamide, the entirety of the components always being 100% by weight.

  本发明涉及一种新型阻燃剂和稳定剂的组合，用于热塑性塑料，其 A 组份包括 25% 至 99.9% （按重量计）的式（I）膦盐和/或式（II）二膦盐和/或这些膦盐的聚合物、 1 其中 R 1 , R 2 相同或不同，并且是 C 1 -C 6 -直链或支链烷基和/或芳基； R 3 是 C 1 -C 10 -烯烃，直链或支链，C 6 -C 10 -烯烃、-烷基烯烃或-芳基烯烃； M 是 Mg、Ca、Al、Sb、Sn、Ge、Ti、Zn、Fe、Zr、Ce、Bi、Sr、Mn、Li、Na、K 和/或质子化氮基； m 为 1 至 4 n 为 1 至 4； x 为 1 至 4、 作为 B 组分，还包括 10%至 75%（按重量计）的含氮增效剂或磷/氮阻燃剂，作为 C 组分，还包括 0.1至50%（按重量计）的碱性或两性氧化物、氢氧化物、碳酸盐、硅酸盐、硼酸盐、锡酸盐、混合氧化物/氢氧化物、氧化物/氢氧化物/碳酸盐、氢氧化物/硅酸盐或氢氧化物/硼酸盐，或这些物质的混合物，还包括作为 D 组分，包含 0 至 5%（按重量计）的亚磷酸盐或亚磷酸盐/亚磷酸酯混合物， 作为 E 组分，包含 0 至 5%（按重量计）的单旦蜡酸酯或盐，作为 F 组分，包含 0.1至5%(重量)的芳香族二羧酸酯或芳香族二羧酸酰胺或芳 香族三羧酸酰胺，各组分的总重量始终为100%(重量)。
• ENAMINE DERIVATIVES FOR USE AS ANTIOXYDANTS FOR POLYMERS
  申请人：Great Lakes Chemical (Europe) GmbH

  公开号：EP0975626A1

  公开（公告）日：2000-02-02
• HALOGENFREIE SULFONSÄUREESTER UND/ODER SULFINSÄUREESTER ALS FLAMMSCHUTZMITTEL, FLAMMSCHUTZMITTELSYNERGISTEN UND RADIKALGENERATOREN IN KUNSTSTOFFEN
  申请人：Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

  公开号：EP3658616A1

  公开（公告）日：2020-06-03